Dr. Hirschfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
16 Sumner Pl
Fl 4
Brooklyn, NY 11206Phone+1 718-732-4050Fax+1 718-881-4445
Education & Training
University of MarylandFellowship, Hematology and Medical Oncology, 2006 - 2009
Temple University HospitalResidency, Internal Medicine, 2002 - 2005
Albert Einstein College of MedicineClass of 2002
Certifications & Licensure
NY State Medical License 2009 - 2026
NJ State Medical License 2022 - 2025
MD State Medical License 2006 - 2010
PA State Medical License 2002 - 2006- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer Start of enrollment: 2014 Jul 01
Publications & Presentations
PubMed
- Cholangiocarcinoma, sequential chemotherapy, and prognostic tests.Howard W Bruckner, Robert De Jager, Elisheva Knopf, Fred Bassali, Abe Book
Frontiers in Oncology. 2024-01-01 - 6 citationsBevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.Howard W. Bruckner, Daniel Gurell, Azriel Hirschfeld
Anticancer Research. 2018-01-01 - 5 citationsTargeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores.Howard W. Bruckner, Azriel Hirschfeld, Myron Schwartz
Anticancer Research. 2016-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
